{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/62d20dbcffef490011c8df4b/65c9a77972a439001766b450?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"89. Spotlight - Biotech: Interview with Dr Jeff Jones from Cullinan Oncology","description":"<p>Today, on this mid-week special, Oncology for the Inquisitive Mind is delighted to welcome Dr. Jeff Jones, a haematologist, oncologist and the Chief Medical Officer of Cullinan Oncology. Biotech companies are at the forefront of novel drug development, and it is fascinating to take a look behind the curtain and glimpse a small part of how targets are chosen and developed. This includes areas of unmet need, including Exon 20 EGFR mutant lung cancer treatment.</p><p><br></p><p>Cullinan Oncology conducts research focused on immuno-oncology and translational cancer medicine, specifically focusing on small molecules and biologics to identify unique targets and develop transformative therapeutics across cancer indications.</p><p><br></p><p>Many thanks to Dr Jones and the team at Cullinan for taking the time to appear on our show.</p><p><br></p><p>For more episodes, resources and blog posts, visit <a href=\"https://open.acast.com/shows/62d20dbcffef490011c8df4b/episodes/www.inquisitiveonc.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>www.inquisitiveonc.com</strong></a></p><p>Please find us on Twitter @InquisitiveOnc!</p><p>If you want us to look at a specific trial or subject, email us at<strong> </strong><a href=\"mailto:inquisitiveonc@gmail.com\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>inquisitiveonc@gmail.com</strong></a></p><p><br></p><p>Art courtesy of Taryn Silver</p><p>Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/</p><p><br></p><p><strong>Disclaimer:</strong> This podcast is for educational purposes only. If you are unwell, seek medical advice.</p>","author_name":"Michael Fernando and Josh Hurwitz"}